![]() Bluebird Bio (BLUE). Focus on genetic diseases and cancer.Other companies are more focused on gene therapy/gene editing rather than actual cell or stem cell therapies so not all of those have been included. Note that some huge companies such as Astellas have substantial stem cell programs, but aren’t cell medicine focused overall so they aren’t listed. Are you a fan of Brainstorm, Celularity or one of many others not mentioned below? Don’t see your favorite on the list? Weigh in with yours in the comments. Obviously, these are just biotechs that have gotten my notice, but there are more out there in this sector. In addition, where possible I’ve included a link to the company site and also links to past posts about the firm on The Niche. I also took a look at their share price changes over the last 12 months too. What are the notable stem cell stocks or biotechs out there? If you love riding ups and downs and are excited about cell research, then you might enjoy at least following some of these stocks.īelow I have a concise list of stem cell and regenerative medicine biotech companies in alphabetical order. I’ve included a snippet in some cases of what they are up to or recent news for each. RMAT designations should make it easier for firms to move forward with their clinical studies. My list stands at 49 such approvals, but more are not yet in the public domain. RMATsĬell therapy firms should be pleased with the rate at which the FDA has been approving their regenerative medicine advanced therapy (RMAT) designations. Many are primarily working on cell therapies for other conditions as well, of course. But if one or a few come up with approved cell therapies for COVID-19 it’ll likely be positively transforming for them and more importantly, potentially help a lot of people. I expect some will go way back down when the biotech COVID bounce fades. ![]() It’s a risky area as the odds are that most cell therapy companies are not going to come up with successful COVID-19 treatments. I guess they’re rolling the dice that some of these firms will develop safe and effective COVID treatments based on cells. Their stocks have zoomed in some cases as investors have been snapping them up. The pandemic has been awful to put it mildly, but it has been an opportunity for many cell therapy biotechs. COVID bounce to cell therapy & stem cell stocks There have been some name changes too, making things somewhat confusing in certain cases. We’ve also seen quite a few acquisitions of cell therapy companies in the past 2 years including Celgene and others. It seems likely that they may do IPOs in coming years. Note that some of the cell therapy biotechs that I’m featuring here are not yet publicly traded, but they are particularly interesting so I’ve decided to include them. So far in 2022, it’s been generally a pretty bad year for stem cell stocks too just as in 2021, which I detail below in a breakdown of results for 2021. Which ones might be acquisition targets? What about the impact of the FDA? How has COVID impacted them? Mostly in very positive, even if likely transient ways. Today I’m highlighting 24 “stem cell stocks”. It is definitely the case in the volatile stem cell and cell therapy arena. This is kind of the standard of “life” as any biotech company. These biotechs have ups and downs, sometimes at the same time. I also am providing links and other info. In today’s post I go over some of the considerations for 24 stem cell and cell therapy firms. Investing in stem cell stocks is not for the timid. Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |